TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology | News

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCode’s lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer. In the … Read more

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology | Business

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced acceptance for publication by Frontiers in Oncology of a case study using TransCode’s lead therapeutic candidate, TTX-MC138, in a feline patient with spontaneous metastatic breast cancer. In the … Read more